Related Experiment Video

Updated: Jun 26, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Proteasome inhibitors therapeutic strategies for cancer

Annamaria D'Alessandro1, Luisa Pieroni, Maurizio Ronci

  • 1IRCCS-Fondazione Santa Lucia Centro di Ricerca sul Cervello, Rome, Italy.

Recent Patents on Anti-Cancer Drug Discovery
|January 20, 2009
PubMed

Insights

Aberrations in the Ubiquitin-Proteasome System (UPS) are linked to diseases like cancer. Proteasome inhibitors (PIs) offer a novel anti-cancer therapy by blocking key cellular pathways and enhancing other treatments.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The Ubiquitin-Proteasome System (UPS) plays a critical role in cellular protein degradation.
  • Dysregulation of the UPS is implicated in the pathogenesis of various human diseases, including cancer and neurodegenerative disorders.
  • The proteasome is recognized as a significant target for therapeutic drug discovery.

Purpose of the Study:

  • To review recent advancements in the development of proteasome inhibitors (PIs) as anti-cancer agents.
  • To highlight novel patented PI compounds and therapeutic intervention strategies.
  • To explore the potential of PIs in treating cancer and inflammatory-related diseases.

Main Methods:

  • Review of pharmacological, preclinical, and clinical data on proteasome inhibitors.
  • Analysis of studies investigating the mechanisms of PI action, including NF-kB pathway inhibition.
  • Examination of research on PI potentiation of other anti-cancer treatments and down-regulation of chemoresistance.

Main Results:

  • Proteasome inhibitors (PIs) demonstrate efficacy by decreasing cellular proliferation and angiogenic cytokine production.
  • PIs induce cancer cell death and inhibit tumor cell adhesion to the stroma.
  • PIs have been shown to potentiate other anti-cancer therapies by down-regulating chemoresistance pathways.

Conclusions:

  • Pharmacological and clinical data support the use of PIs in anti-cancer strategies.
  • PIs represent a promising therapeutic approach for cancer and inflammatory-related diseases.
  • Ongoing research focuses on novel PI compounds and optimized therapeutic protocols for enhanced efficacy.

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...